A Study of Zidesamtinib (NVL-520)
Phase 1/2
359
about 7 years
12+
20 sites in CA, CO, DC +13
About this study
This trial is testing a treatment called zidesamtinib (NVL-520) in people with advanced NSCLC and other solid tumors that have ROS1 rearrangements. The goal is to see if the treatment is safe, how well it works, and what dose is best for further trial.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Zidesamtinib (NVL-520)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
kinase inhibitor
Primary: Maximum Tolerated Dose (MTD) (Phase 1), Objective Response Rate (ORR) (Phase 2), Recommended Phase 2 Dose (RP2D)
Secondary: Clinical benefit rate (CBR), Duration of response (DOR), Half-life (t1/2) of NVL-520, Intracranial objective response rate (IC-ORR), Maximum plasma concentration (Cmax) of NVL-520, Number of participants with treatment-emergent adverse events, as assessed by CTCAE, v5.0, Objective response rate (ORR), Oral clearance (CL/F) of NVL-520
Oncology